We serve Chemical Name:1,3,5-Trichloro(2H3)benzene CAS:1198-60-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1,3,5-Trichloro(2H3)benzene
CAS.NO:1198-60-3
Synonyms:1,3,5,-Trichlor-trideuterio-benzol;1,3,5-Trichlor-trideutero-benzol;1,3,5-trichloro-2,4,6-trideuterio-benzene;<D3>-1,3,5-trichlorobenzene;1,3,5-Trichlor-2,4,6-trideuterio-benzol;1,3,5-Trichlorobenzene-d3;MFCD00075391;1,3,5-Trichloro(H)benzene;Benzene-1,3,5-d, 2,4,6-trichloro-;DE970
Molecular Formula:C6Cl3D3
Molecular Weight:184.465
HS Code:
Physical and Chemical Properties:
Melting point:56-60ºC(lit.)
Boiling point:211.3±20.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.567
PSA:
Exact Mass:182.948868
LogP:4.04
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3077 9/PG 3
Packing Group:
Contact us for information like 1,3,5,-Trichlor-trideuterio-benzol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,DE970 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,-1,3,5-trichlorobenzene Use and application,Benzene-1,3,5-d, 2,4,6-trichloro- technical grade,usp/ep/jp grade.
Related News: AstraZeneca acquired global rights to anifrolumab through an exclusive license and collaboration agreement with Medarex, Inc. in 2004. Medarex was acquired by Bristol-Myers Squibb in 2009. 1,2-Dichloro-4-methyl-3,5-dinitrobenzene manufacturers Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly. 2-BROMO-1,4-DIMETHYL-1H-IMIDAZOLE suppliers He joins us at a pivotal time as our Jinkō® platform goes from strength to strength as we expand our portfolio of partnerships. Grégoire’s strategic and operational expertise will be a vital part of our future success in accelerating and de-risking clinical trials. 2-(3-Methylpiperidin-1-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine vendor & factory.
